Search

Displaying results 5351 - 5360 of 10000 in total
  1. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  2. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  3. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). … The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.

  4. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  5. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.

  6. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. … It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

  7. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. … Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  8. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells.

  9. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. … T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.

  10. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A196128] Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).[L16343] … [A220118, A220128] Although ifenprodil has received considerable interest in its potential neuromodulatory activities in psychiatric conditions, including dependency[A220138] and depression,[A220143